Grifols, S.A. GIKLY
5.55 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
5.77 Day range 5.77
5.06 52-week range 6.85
- YTD
- -9.90%
- 1 year
- -18.98%
News
seekingalpha.com Grifols: Plasma, Profits, And Recovery Gathering Momentum Grifols remains a speculative 'BUY' with a €20/share price target, offering over 20% annual upside if growth continues. GIKLY has delivered strong 3Q26 results: revenue above €2B quarterly, EBITDA up…
seekingalpha.com Grifols, S.A. (GIKLY) Q3 2026 Earnings Call Transcript Grifols, S.A. (GIKLY) Q3 2026 Earnings Call Transcript
seekingalpha.com Oakmark International Small Cap Strategy Q2 2026 Portfolio Update The portfolio's return was 5.34% (net) for the reporting period. We initiated the following positions: Birkenstock Holding, Dormakaba, Hiab, Reply, SATS Ltd., and Scout24. We eliminated the following…
seekingalpha.com Grifols, S.A. (GIKLY) Q2 2026 Earnings Call Transcript Grifols, S.A. (GIKLY) Q2 2026 Earnings Call Transcript
seekingalpha.com Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade) First-quarter results were broadly in line with expectations, supported by strong growth in the Biopharma division, particularly immunoglobulins, where products such as Gamunex and Yimmugo continue…
globenewswire.com Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S. BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S.…
seekingalpha.com Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript